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Background
Interleukin-10 (IL-10) is a potent immunoregulatory cytokine, with promoter polymorphisms that have previously been associated with HIV-1 susceptibility and pathogenesis. Association of IL-10 SNPs with markers of CD4, CD8 and B cell activation has not previously been investigated.
Methods
Two IL-10 polymorphisms were genotyped by TaqMan allelic discrimination and markers of activation of CD4, CD8 and B cells were measured in 63 individuals using flow cytometry. The following monoclonal antibody combinations were used: anti-CD3 Pac-blue, anti-CD38 PE-Cy7, anti-HLA-DR ACP-Cy7, anti-CD95 PE, anti-CD19 Alexa-700, anti-IgG PE-Cy5, anti-PD-1 APC, anti-Ki67 FITC, anti-CD4 Qdot605 and anti-CD8 Qdot655.
Results
Previous studies on this cohort showed a significant association between -1082GG and higher median IL-10 expression, compared to the -1082AA/AG (p= 0.0006). The -592AA and -1082AA (both previously shown to be associated with low-IL-10 production) had significantly higher median expression of HLA-DR on CD4 and CD8 cells respectively, compared to the other genotypes 
Conclusion
These data suggest that IL-10 polymorphisms that affect cytokine production and HIV pathogenesis may affect markers of immune activation and exhaustion in response to antigen, and suggest a beneficial role for IL-10 in chronic HIV infection. Further studies on association between IL-10 and the quality and magnitude of immune responses in HIV infection are needed.
